IDEXX Laboratories, Inc. (IDXX, Financial) has announced a significant leadership transition within its financial department. Brian P. McKeon, the company's Executive Vice President, Chief Financial Officer, and Treasurer, has notified the company of his intention to retire effective June 1, 2025. Mr. McKeon has been a pivotal figure at IDEXX since January 2014, having previously served on the company's Board of Directors from July 2003 to December 2013.
In preparation for his retirement, Mr. McKeon will step down from his current roles as Chief Financial Officer, Treasurer, principal financial officer, and principal accounting officer on March 1, 2025. He will continue to serve as Executive Vice President and Special Advisor to ensure a smooth transition until his retirement date. His responsibilities for the Water, Livestock, Poultry and Dairy, and OPTI Medical businesses will be transferred to Michael Lane, Executive Vice President and General Manager, Reference Laboratories and Information Technology, effective January 1, 2025.
Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group Finance, has been appointed as the new Executive Vice President, Chief Financial Officer, and Treasurer, effective March 1, 2025. Mr. Emerson, age 41, has been with IDEXX since November 2015, where he has led the finance organization for the Companion Animal Group business. He expanded his role in March 2020 to include corporate finance functions such as investor relations, treasury, financial planning and analysis, and financial reporting.
Before joining IDEXX, Mr. Emerson held significant finance roles at Medtronic plc and Covidien plc. He holds a bachelor's degree in accounting and business management from Northeastern University. As the new CFO, Mr. Emerson will receive an annual base salary of $550,000, participate in the company's Executive Incentive Plan with a target cash bonus of 75% of his base salary for fiscal 2025, and be eligible for annual equity awards under the company's Stock Incentive Plan.
There are no arrangements or understandings between Mr. Emerson and any other persons regarding his appointment, and he has no material interest in any transaction requiring disclosure. This transition marks a new chapter for IDEXX Laboratories as it continues to strengthen its leadership team.
Should you invest in IDEXX Laboratories Inc (IDXX, Financial) right now? Before you do it, it’s important to understand the business profitability and stock valuations, and find out what the warning signs are about. See the in-depth IDEXX Laboratories Inc (IDXX) stock research here.
